Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas

Neurochemistry International

Volumn 56, Issue 6-7, 2010, Pages 829-833

  De Jesús, Maider López ^a,b   Hostalot, Cristina ^a,c   Garibi, Jesús M ^a,c   Sallés, Joan ^a,b   Meana, J Javier ^a,b   Callado, Luis F ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

Author keywords

Cannabinoids; Glial tumors; Human brain

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); SULFUR 35;

ARTICLE; ASTROCYTOMA; BINDING KINETICS; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADULT; AGED; ASTROCYTOMA; BENZOXAZINES; BLOTTING, WESTERN; BRAIN CHEMISTRY; BRAIN NEOPLASMS; CANNABINOIDS; CELL MEMBRANE; FEMALE; GLIOBLASTOMA; GLIOMA; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MALE; MENINGIOMA; MIDDLE AGED; MORPHOLINES; NAPHTHALENES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SULFUR RADIOISOTOPES;

EID: 77952287702     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.03.007     Document Type: Article

References (39)

1. Amar M.B. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethnopharmacol. 2006, 105:1-25.
2. Badie B., Schartner J. Role of microglia in glioma biology. Microsc. Res. Tech. 2001, 54:106-113.
3. 2 receptors and fatty acida mide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 2003, 23:11136-11141.
4. 2 receptors in human brain inflammation. Br. J. Pharmacol. 2008, 153:277-285.
5. Breivogel C.S., Griffi, n G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 2001, 60:155-163.
6. Burnet N.G., Lynch A.G., Jefferies S.J., Price S.J., Jones P.H., Antoun N.M., Xuereb J.H., Pohl U. High grade glioma: imaging combined with pathological grade defines management and predicts prognosis. Radiother. Oncol. 2007, 85:371-378.
7. 9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006, 66:6615-6621.
8. Canoll P., Goldman J.E. The interface between glial progenitors and gliomas. Acta Neuropathol. 2008, 116:465-477.
9. Cudaback E., Stella N. Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue. Mol. Neurobiol. 2007, 36:36-44.
10. 2) expression in adult and pediatric brain tumors. Brain Res. 2007, 1137:161-169.
11. 2 receptor: a new target for controlling neural cell survival. Trends Pharmacol. Sci. 2007, 28:39-45.
12. Galve-Roperh I., Sánchez C., Cortés M.L., Gómez del Pulgar T., Izquierdo M., Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase action. Nat. Med. 2000, 6:313-318.
13. 2 receptors in crude and synaptosomal membranes from human cerebral cortex. Neuropharmacology 2001, 40:686-695.
14. Glass M., Faull R.L., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 1993, 56:523-527.
15. Glass M., Dragunow M., Faull R.L.M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
16. 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer 2006, 95:197-203.
17. Held-Feindt J., Dörner L., Sahan G., Mehdorn H.M., Mentlein R. Cannabinoid receptors in human astroglial tumors. J. Neurochem. 2006, 98:886-893.
18. Herkenham M., Lynn A.B., Little M.D., Jhonson M.R., Melvin L.S., De Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:1932-1936.
19. 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural. Transm. 2003, 110:1279-1288.
20. Kaminski N.E., Abood M.E., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 1992, 42:736-742.
21. López de Jesús M., Sallés J., Meana J.J., Callado L.F. Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates. Neuroscience 2006, 140:635-643.
22. Makriyannis A., Mechoulam R., Piomelli D. Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology 2005, 48:1068-1071.
23. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
24. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
25. 2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006, 20:1773-1779.
26. Petersen G., Moesgaard B., Schmid P.C., Schmid H.H.O., Broholm H., Kosteljanetz M., Hansen H.S. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J. Neurochem. 2005, 93:299-309.
27. Richfield E.K., Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 1994, 36:577-584.
28. Rodriguez F., Rozas I., Ortega J.E., Meana J.J., Callado L.F. Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists, 1: towards new antidepressants with heteroatomic linkers. J. Med. Chem. 2007, 50:4516-4527.
29. 35S]Guanylyl-5′-O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience 1998, 84:1075-1083.
30. 2 cannabinoid receptor. Cancer Res. 2001, 61:5784-5789.
31. Schley M., Ständer S., Kerner J., Vajkoczy P., Schüpfer G., Dusch M., Schmelz M., Konrad C. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res. Bull. 2009, 79:333-337.
32. Schor N.F. Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol. Therapeut. 2009, 121:253-264.
33. Skaper S.D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., Leon A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3984-3989.
34. Stella N. Cannabinoid signaling in glial cells. Glia 2004, 48:267-277.
35. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
36. Walsh D., Nelson K.A., Mahmoud F.A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003, 11:137-143.
37. Wang X., Dow-Edwards D., Keller E., Hurd Y.L. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 2003, 118:681-694.
38. Westlake T.M., Howlett A.C., Bonner T.I., Matsuda L.A., Herkenhan M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 1994, 63:637-652.
39. Yang I., Han S.J., Kaur G., Crane C., Parsa A.T. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci. 2010, 17:6-10.